Whole-genome sequencing in pharmacogenetics

Pharmacogenomics

Volumn 14, Issue 4, 2013, Pages 345-348

  Urban, Thomas J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

clinical sequencing; drug development; next generation sequencing; NGS; pharmacogenomics; WES; WGS; whole exome sequencing

Indexed keywords

CYTOCHROME P450 2D6; GENOMIC DNA;

CLINICAL DECISION MAKING; CLINICAL PRACTICE; COPY NUMBER VARIATION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; CYP2D6 GENE; DRUG EFFICACY; DRUG RESPONSE; GENE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC PROCEDURES; GENETIC RISK; GENETIC VARIABILITY; GENOME ANALYSIS; HUMAN; INTERMETHOD COMPARISON; MEDICAL INFORMATION; MEDICAL RESEARCH; PHARMACOGENETICS; PHARMACOGENOMICS; PHENOTYPE; PREDICTION; REVIEW; RISK ASSESSMENT; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; WHOLE EXOME SEQUENCING;

BIOMARKERS, PHARMACOLOGICAL; DRUG TOXICITY; GENETIC MARKERS; GENOME, HUMAN; GENOME-WIDE ASSOCIATION STUDY; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; PHARMACOGENETICS;

EID: 84874601829     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.211     Document Type: Review

References (16)

1. Maher B. Personal genomes: The case of the missing heritability. Nature 456(7218), 18-21 (2008
2. Goldstein DB. Common genetic variation and human traits. N. Engl. J. Med. 360(17), 1696-1698 (2009
3. Link E, Parish S, Armitage J et al. SLCO1B1 variants and statin-induced myopathy - A genomewide study. N. Engl. J. Med. 359(8), 789-799 (2008
4. Daly AK, Donaldson PT, Bhatnagar P et al. HLA-B&z.ast;5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat. Genet. 41(7), 816-819 (2009
5. Rabbani B, Mahdieh N, Hosomichi K et al. Next-generation sequencing: Impact of exome sequencing in characterizing Mendelian disorders. J. Hum. Genet. 57(10), 621-632 (2012
6. Xu B, Ionita-Laza I, Roos JL et al. De novo gene mutations highlight patterns of genetic and neural complexity in schizophrenia. Nat. Genet. 44(12), 1365-1369 (2012
7. Holm H, Gudbjartsson DF, Sulem P et al. A rare variant in MYH6 is associated with high risk of sick sinus syndrome. Nat. Genet. 43(4), 316-320 (2011
8. Durbin RM, Abecasis GR, Altshuler DL et al. A map of human genome variation from population-scale sequencing. Nature 467(7319), 1061-1073 (2010
9. Zhu M, Need AC, Han Y et al. Using ERDS to infer copy-number variants in high-coverage genomes. Am. J. Hum. Genet. 91(3), 408-421 (2012
10. Johansson I, Lundqvist E, Bertilsson L et al. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl Acad. Sci. USA 90(24), 11825-11829 (1993
11. Lucena MI, Molokhia M, Shen Y et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology (2011
12. McCormack M, Alfirevic A, Bourgeois S et al. HLA-A&z.ast;3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N. Engl. J. Med. 364(12), 1134-1143 (2011
13. Spraggs CF, Budde LR, Briley LP et al. HLA-DQA1&z.ast;02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J. Clin. Oncol. 29(6), 667-673 (2011
14. Bamshad MJ, Ng SB, Bigham AW et al. Exome sequencing as a tool for Mendelian disease gene discovery. Nat. Rev. Genet. 12(11), 745-755 (2011
15. von Bubnoff A. Next-generation sequencing: The race is on. Cell 132(5), 721-723 (2008
16. Ong FS, Deignan JL, Kuo JZ et al. Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: A challenge for clinical implementation. Pharmacogenomics 13(4), 465-475 (2012